<DOC>
	<DOC>NCT00389441</DOC>
	<brief_summary>The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine</brief_summary>
	<brief_title>Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer</brief_title>
	<detailed_description>Additional study details: assess safety and efficacy</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Radioiodinerefractory metastatic or unresectable locallyadvanced thyroid cancer At least 1 measurable target lesion, as defined by RECIST Thyroid lymphoma Previous treatment with antiangiogenesis agents No myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, deep vein thrombosis or pulmonary embolism within 12 months prior.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>VEGFR inhibitor</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
	<keyword>anti-angiogenic</keyword>
	<keyword>carcinoma</keyword>
	<keyword>papillary</keyword>
	<keyword>follicular</keyword>
	<keyword>medullary</keyword>
	<keyword>anaplastic</keyword>
</DOC>